- Home
- DDL vs MYGN Comparison
DDL vs MYGN Comparison
Compare DDL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDL | MYGN |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 546.3M | 444.2M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DDL | MYGN |
|---|---|---|
| Price | $2.70 | $5.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 436.4K | ★ 1.1M |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $7.06 | $6.89 |
| Revenue Next Year | $14.86 | $5.35 |
| P/E Ratio | $16.08 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.65 | $3.76 |
| 52 Week High | $3.41 | $8.59 |
Technical Indicators
Market Signals| Indicator | DDL | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 58.52 |
| Support Level | $2.58 | $4.25 |
| Resistance Level | $2.78 | $5.60 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 72.09 | 79.05 |
Price Performance
Historical ComparisonAbout DDL Dingdong (Cayman) Limited (each two representing three)
Dingdong (Cayman) Ltd is the fastest growing on-demand e-commerce company in China. The company directly provides users and households with fresh produce, meat and seafood, and other daily necessities through a convenient shopping experience supported by an extensive self-operated frontline fulfillment grid. It recognizes revenues from product sales of fresh groceries and other daily necessities through Dingdong Fresh APP and mini-programs and membership services.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.